NCI Definition: An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland. 
Mucinous adenocarcinomas most frequently harbor alterations in KRAS, TP53, GNAS, APC, and SMAD4 .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and TP53 Missense are the most common alterations in mucinous adenocarcinoma .
There is 1 clinical trial for mucinous adenocarcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains mucinous adenocarcinoma as an inclusion criterion, 1 is phase 1 (1 open).
Irinotecan sucrosofate is the most common intervention in mucinous adenocarcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.